These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Development of eptifibatide. Scarborough RM Am Heart J; 1999 Dec; 138(6 Pt 1):1093-104. PubMed ID: 10577440 [TBL] [Abstract][Full Text] [Related]
8. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Phillips DR; Teng W; Arfsten A; Nannizzi-Alaimo L; White MM; Longhurst C; Shattil SJ; Randolph A; Jakubowski JA; Jennings LK; Scarborough RM Circulation; 1997 Sep; 96(5):1488-94. PubMed ID: 9315536 [TBL] [Abstract][Full Text] [Related]
10. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa. O'Shea JC; Tcheng JE Expert Opin Pharmacother; 2002 Aug; 3(8):1199-210. PubMed ID: 12150697 [TBL] [Abstract][Full Text] [Related]
11. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Harrington RA Am J Cardiol; 1997 Aug; 80(4A):34B-38B. PubMed ID: 9291244 [TBL] [Abstract][Full Text] [Related]
12. Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa. Lorenz TJ; Macdonald F; Kitt MM Clin Ther; 1999 Jan; 21(1):128-37. PubMed ID: 10090430 [TBL] [Abstract][Full Text] [Related]
13. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
14. Double loading of cyclosporine A in liposomes using cyclodextrin complexes. Malaekeh-Nikouei B; Davies N PDA J Pharm Sci Technol; 2009; 63(2):139-48. PubMed ID: 19634352 [TBL] [Abstract][Full Text] [Related]
15. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Storey RF; Wilcox RG; Heptinstall S Circulation; 1998 Oct; 98(16):1616-21. PubMed ID: 9778326 [TBL] [Abstract][Full Text] [Related]
16. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Tcheng JE Am J Cardiol; 1997 Aug; 80(4A):21B-28B. PubMed ID: 9291242 [TBL] [Abstract][Full Text] [Related]
17. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation. Lev EI; Hasdai D; Scapa E; Tobar A; Assali A; Lahav J; Battler A; Badimon JJ; Kornowski R J Am Coll Cardiol; 2004 Mar; 43(6):966-71. PubMed ID: 15028351 [TBL] [Abstract][Full Text] [Related]
18. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. Dalby M; Montalescot G; Bal dit Sollier C; Vicaut E; Soulat T; Collet JP; Choussat R; Gallois V; Drobinski G; Drouet L; Thomas D J Am Coll Cardiol; 2004 Jan; 43(2):162-8. PubMed ID: 14736431 [TBL] [Abstract][Full Text] [Related]
19. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM; Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393 [TBL] [Abstract][Full Text] [Related]
20. RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer. Feng C; Li X; Dong C; Zhang X; Zhang X; Gao Y Drug Des Devel Ther; 2015; 9():4613-20. PubMed ID: 26316700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]